Literature DB >> 26559322

Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease.

Hiroaki Hayashi1, Chihiro Mitsui2, Eiji Nakatani3, Yuma Fukutomi2, Keiichi Kajiwara2, Kentaro Watai4, Kiyoshi Sekiya2, Takahiro Tsuburai2, Kazuo Akiyama2, Yoshinori Hasegawa5, Masami Taniguchi6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26559322     DOI： 10.1016/j.jaci.2015.09.034

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  24 in total

Review 1.  Update on Aspirin-Exacerbated Respiratory Disease.

Authors:  Katharine M Woessner
Journal:  Curr Allergy Asthma Rep       Date:  2017-01       Impact factor: 4.806

Review 2.  Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations.

Authors:  Joshua M Levy; Luke Rudmik; Anju T Peters; Sarah K Wise; Brian W Rotenberg; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2016-08-02       Impact factor: 3.858

3.  Effectiveness of endoscopic sinus surgery and aspirin therapy in the management of aspirin-exacerbated respiratory disease.

Authors:  Auddie M Sweis; Tran B Locke; Kevin I Ig-Izevbekhai; Theodore C Lin; Ankur Kumar; Jennifer E Douglas; Andrew M Corr; Alyssa M Civantos; Siddhant H Tripathi; David W Kennedy; Michael A Kohanski; James N Palmer; Nithin D Adappa; John V Bosso
Journal:  Allergy Asthma Proc       Date:  2021-03-01       Impact factor: 2.587

Review 4.  Aspirin-exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future.

Authors:  Joshua L Kennedy; Ashley N Stoner; Larry Borish
Journal:  Am J Rhinol Allergy       Date:  2016-11-01       Impact factor: 2.467

5.  IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Daniel F Dwyer; Jose Ordovas-Montanes; Howard R Katz; Erin Lewis; Marko Vukovic; Juying Lai; Lora G Bankova; Neil Bhattacharyya; Alex K Shalek; Nora A Barrett; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2020-03-19       Impact factor: 10.793

Review 6.  Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function.

Authors:  Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2019-10       Impact factor: 10.793

Review 7.  Biologics in chronic rhinosinusitis with nasal polyposis.

Authors:  Tanya M Laidlaw; Kathleen M Buchheit
Journal:  Ann Allergy Asthma Immunol       Date:  2019-12-09       Impact factor: 6.347

Review 8.  The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

Authors:  Whitney W Stevens; Elina Jerschow; Alan P Baptist; Larry Borish; John V Bosso; Kathleen M Buchheit; Katherine N Cahill; Paloma Campo; Seong H Cho; Anjeni Keswani; Joshua M Levy; Anil Nanda; Tanya M Laidlaw; Andrew A White
Journal:  J Allergy Clin Immunol       Date:  2020-12-09       Impact factor: 10.793

Review 9.  Local immunoglobulin production in nasal tissues: A key to pathogenesis in chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Kathryn E Hulse
Journal:  Ann Allergy Asthma Immunol       Date:  2020-10-13       Impact factor: 6.347

Review 10.  Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.

Authors:  Ryan Eid; Carol H Yan; Whitney Stevens; Taylor A Doherty; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2021-08       Impact factor: 14.290
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.